SEC Form 4 · accession 0000899243-19-004395

TCR2 THERAPEUTICS INC. · TCRR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Ansbert Gadicke

Director · 10% Owner

Period of report

Feb 19, 2019

Accepted (ET)

Feb 21, 2019 · 4:52 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001750019

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Feb 19, 2019	C	79,644	—	A	79,644	I	See Footnote
Common Stock^F1,F3	Feb 19, 2019	C	52,469	—	A	52,469	I	See Footnote
Common Stock^F1,F4	Feb 19, 2019	C	146,447	—	A	146,447	I	See Footnote
Common Stock^F1,F5	Feb 19, 2019	C	2,195,681	—	A	2,195,681	I	See Footnote
Common Stock^F1,F6	Feb 19, 2019	C	351,155	—	A	351,155	I	See Footnote
Common Stock^F1,F7	Feb 19, 2019	C	2,421,775	—	A	2,421,775	I	See Footnote
Common Stock^F8,F2	Feb 19, 2019	C	9,291	—	A	88,935	I	See Footnote
Common Stock^F8,F3	Feb 19, 2019	C	5,247	—	A	57,716	I	See Footnote
Common Stock^F8,F4	Feb 19, 2019	C	17,085	—	A	163,532	I	See Footnote
Common Stock^F8,F5	Feb 19, 2019	C	256,163	—	A	2,451,844	I	See Footnote
Common Stock^F8,F6	Feb 19, 2019	C	35,115	—	A	386,270	I	See Footnote
Common Stock^F8,F7	Feb 19, 2019	C	282,540	—	A	2,704,315	I	See Footnote
Common Stock^F9	Feb 19, 2019	P	1,373,333	$15.00	A	1,569,235	I	See Footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F1,F2	—	Feb 19, 2019	C	493,306	D	—	—	Common Stock	79,644	I
Series A Preferred Stock^F1,F3	—	Feb 19, 2019	C	325,002	D	—	—	Common Stock	52,469	I
Series A Preferred Stock^F1,F4	—	Feb 19, 2019	C	907,073	D	—	—	Common Stock	146,447	I
Series A Preferred Stock^F1,F5	—	Feb 19, 2019	C	13,599,621	D	—	—	Common Stock	2,195,681	I
Series A Preferred Stock^F1,F6	—	Feb 19, 2019	C	2,174,998	D	—	—	Common Stock	351,155	I
Series A Preferred Stock^F1,F7	—	Feb 19, 2019	C	15,000,000	D	—	—	Common Stock	2,421,775	I
Series B Preferred Stock^F8,F2	—	Feb 19, 2019	C	57,552	D	—	—	Common Stock	9,291	I
Series B Preferred Stock^F8,F3	—	Feb 19, 2019	C	32,500	D	—	—	Common Stock	5,247	I
Series B Preferred Stock^F8,F4	—	Feb 19, 2019	C	105,825	D	—	—	Common Stock	17,085	I
Series B Preferred Stock^F8,F5	—	Feb 19, 2019	C	1,586,623	D	—	—	Common Stock	256,163	I
Series B Preferred Stock^F8,F6	—	Feb 19, 2019	C	217,500	D	—	—	Common Stock	35,115	I
Series B Preferred Stock^F8,F7	—	Feb 19, 2019	C	1,750,000	D	—	—	Common Stock	282,540	I

Explanation of responses

F1Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
F2The reported securities are owned directly by MPM Asset Management Investors BV2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F3The reported securities are owned directly by MPM Asset Management Investors SunStates Fund LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F4The reported securities are owned directly by MPM BioVentures 2014 (B), L.P. MPM BioVentures 2014 GP LLC is the general partner of MPM BioVentures 2014 (B), L.P. MPM BioVentures 2014 LLC is the managing member of MPM BioVentures 2014 GP LLC. The Reporting Person is a member of MPM BioVentures 2014 LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F5The reported securities are owned directly by MPM BioVentures 2014, L.P. MPM BioVentures 2014 GP LLC is the general partner of MPM BioVentures 2014, L.P. MPM BioVentures 2014 LLC is the managing member of MPM BioVentures 2014 GP LLC. The Reporting Person is a member of MPM BioVentures 2014 LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F6The reported securities are owned directly by MPM SunStates Fund, L.P. MPM SunStates Fund GP LLC is the general partner of MPM SunStates Fund, L.P. MPM SunStates GP Managing Member LLC is the managing member of MPM SunStates Fund GP LLC. The Reporting Person is a member of MPM SunStates Fund GP LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F7The reported securities are held directly by UBS Oncology Impact Fund, L.P. The general partner of UBS Oncology Impact Fund, L.P. is Oncology Impact Fund (Cayman) Management L.P. The general partner of Oncology Impact Fund (Cayman) Management L.P. is MPM Oncology Impact Management LP. The general partner of MPM Oncology Impact Management LP is MPM Oncology Impact Management GP LLC. The Reporting Person is the managing director of MPM Oncology Impact Management GP LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F8Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
F9The reported securities are owned directly by MPM Asset Management LLC. The Reporting Person is a member of MPM Asset Management LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.